Dr. Crawford and his team concluded that the pooled analysis showed that in men with metastatic disease alkaline phosphatase was reduced to a greater degree with degarelix and the overall probability of fracture and incidence of joint-related adverse events were significantly lower in those men treated with degarelix compared to LHRH agonists.
“This retrospective study outlines a number of benefits of an antagonist over an agonist. Thus, there are distinct advantages of this method for androgen ablation in men with prostate cancer,” said Dr. Crawford.
Overall, the latest research presented at the GU Symposium showed that progress is being made not only in the development of newer therapies, but also in the ways these therapies are combined to elicit improved patient response and outcomes.
1) Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18.
2) Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.
3) Scher HI, Fizazi K, Saad F, et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the Phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Abstract 899.Presented at The European Society for Medical Oncology; September 28-October2, 2012; Vienna, Austria.
4) Klotz L, Boccon-Gibod L, Shore ND, et al.The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.
5) Van Poppel H. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res. 2010 Jan 25;2:39-52.